Luis Flavio Fabrini Paleare

Luis Flavio Fabrini Paleare

Auto-generated profile, based on publicly available information

Luis Flavio Fabrini Paleare

Pontifícia Universidade Católica do Paraná, Escola de Medicina, Departamento de Medicina Interna, Curitiba PR, Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in Stroke
Verified
Journal Article
Closed access
AGAhmet Günkan
Ahmet Günkan
MFMarcio Yuri Ferreira
Marcio Yuri Ferreira
MVMarina Vilardo
Marina Vilardo
LSLuca Scarcia
Luca Scarcia
JBJhon E. Bocanegra-Becerra
Jhon E. Bocanegra-Becerra
Claude BaronClaude Baron
Claude Baron
BACKGROUND: A minority of patients with stroke qualify for intravenous thrombolysis (IVT) within 4.5-hour window. The safety and efficacy of IVT beyond this period have not been well studied. METHODS: We systematically searched MEDLINE, Embase, Cochrane, and ClinicalTrials.gov for relevant randomized clinical trials. Randomized clinical trials comparing IVT versus standard medical care in patients with ischemic stroke beyond 4.5 hours of symptom onset or last known well without mechanical thrombectomy (MT) were included. Primary outcomes were excellent (modified Rankin Scale score of 0–1) and good (modified Rankin Scale score of 0–2) functional outcomes at 90 days, symptomatic intracerebral hemorrhage (sICH), and death at 90 days. Pooled odds ratios (ORs) with 95% CIs were calculated using a random-effects model. Heterogeneity was assessed by Q test and quantified by I ² values. RESULTS: Eight randomized clinical trials (1742 patients; mean age, 69.8±9 years, 63.5% men) were included. Compared with standard medical care, IVT achieved higher rates of excellent (OR, 1.43 [95% CI, 1.17–1.75]; Q =2.30; P =0.94; I 2 =0%) and good functional outcomes (OR, 1.36 [95% CI, 1.12–1.66]; Q =2.07; P =0.96; I 2 =0%) at 90 days but also increased sICH rates (OR, 4.25 [95% CI, 1.67–10.84], Q =0.48; P =0.99; I 2 =0%). Mortality at 90 days did not significantly differ between treatment groups (OR, 1.28 [95% CI, 0.87–1.89]; Q =4.63; P =0.59; I 2 =0%). Subanalyses yielded numerically higher odds of excellent functional outcomes when patients were selected with perfusion imaging (3 studies, OR, 1.45 [95% CI, 1.08–1.94]) compared with diffusion-weighted imaging–fluid-attenuated inversion recovery mismatch (3 studies, OR, 1.34 [95% CI, 0.94–1.91]) and when treated with tenecteplase (3 studies, OR, 1.47 [95% CI, 1.06–2.04]) compared with alteplase (5 studies, OR, 1.38 [95% CI, 1.08–1.78]). CONCLUSIONS: IVT for ischemic stroke beyond 4.5 hours, without MT, led to increased odds of excellent and good functional outcomes compared with standard medical care, despite higher odds of sICH, and a nonsignificant numerical increase in mortality.

19 October 2024 in World Neurosurgery
Verified
Journal Article
Closed access
Inibehe Ime OkonInibehe Ime Okon
Inibehe Ime Okon
MOMahmoud Osama
Mahmoud Osama
AAAsangaedem Akpan
Asangaedem Akpan
LPLuis Flavio Fabrini Paleare
Luis Flavio Fabrini Paleare
MFMarcio Yuri Ferreira
Marcio Yuri Ferreira
DLDon Eliseo Lucero-Prisno
Don Eliseo Lucero-Prisno

9 January 2026 in Tissue Engineering and Regenerative Medicine
Verified
Journal Article
Closed access
PDF file
MFMarcio Yuri Ferreira
Marcio Yuri Ferreira
LPLuis F. Fabrini Paleare
Luis F. Fabrini Paleare
YSYasmin P. Silva
Yasmin P. Silva
KLKaike Lobo
Kaike Lobo
LCLeonardo Januário Campos Cardoso
Leonardo Januário Campos Cardoso
NBNetanel Ben-Shalom
Netanel Ben-Shalom

27 February 2026 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
PLPatricia Do Rocio Litça
Patricia Do Rocio Litça
ACAna C. de Souza Crippa
Ana C. de Souza Crippa
APAdrielle Holler Pykocz
Adrielle Holler Pykocz
LPLuis F. Fabrini Paleare
Luis F. Fabrini Paleare
MSMarcio Vieira Sanches Silva
Marcio Vieira Sanches Silva
GFGustavo Leite Franklin
Gustavo Leite Franklin
Cerebral palsy (CP), a term coined by William John Little in 1843, represents a group of non-progressive motor disorders resulting from early brain injury. Beyond its medical characterization, there were early artistic depictions, such as Egyptian reliefs and medieval religious scenes, portraying individuals with asymmetric or contracted limbs mainly through symbolic or moral lenses. During the Renaissance and Baroque periods, artists including Dürer and Velázquez subtly represented physical diversity, though without explicit medical context. Literary portrayals evolved from mythological or moral allegory (e.g., Hephaestus, hagiographies) to empathetic narratives of individuality and inclusion, as seen in Tiny Tim, present in A Christmas Carol, written by Charles Dickens, and Draper's Out of My Mind. In modern times, artists and writers living with CP transformed disability into a means of self-expression and social critique.

23 March 2026 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
LPLuis F. Fabrini Paleare
Luis F. Fabrini Paleare
JPJosé Luiz Pedroso
José Luiz Pedroso
FRFlávia de Paiva Santos Rolim
Flávia de Paiva Santos Rolim
NKNatália R. Karpejany
Natália R. Karpejany
CCCarlos Henrique Camargo
Carlos Henrique Camargo
GFGustavo L. Franklin
Gustavo L. Franklin
Ozzy Osbourne, the legendary frontman of Black Sabbath, publicly revealed his diagnosis of Parkinson's disease (PD) in 2020, offering visibility to a complex neurodegenerative condition. His case, later linked to a mutation in the PARK2 (parkin) gene, presented atypically with a later age of onset, contributing to ongoing discussions about the phenotypic variability of genetic forms of PD. Beyond medical narratives, Osbourne's openness and philanthropy—culminating in a benefit concert that raised $190 million for Parkinson's and pediatric charities—played a transformative role in destigmatizing the disease. This article explores the scientific and social impact of Osbourne's disclosure, highlighting the role of PARK2 in mitochondrial homeostasis, synaptic integrity, and tumor suppression. We also examine his pursuit of experimental stem cell therapy, discussing its scientific basis, ethical considerations, and current clinical research landscape.

2 December 2025 in Interventional Neuroradiology
Verified
Journal Article
Closed access
LBLeonardo Bo Brenner
Leonardo Bo Brenner
VOVictor Arthur Ohannesian
Victor Arthur Ohannesian
BNBernardo Vieira Nogueira
Bernardo Vieira Nogueira
JLJoão Artur Mateus Linhares
João Artur Mateus Linhares
SBSávio Batista
Sávio Batista
Raphael BertaniRaphael Bertani
Raphael Bertani
Introduction: In recent decades, neurovascular practice has shifted from open surgical procedures to interventional neuroradiology. Within this evolving landscape, two journals—Interventional Neuroradiology (INR) and Journal of NeuroInterventional Surgery (JNIS)—have become central platforms for disseminating impactful research. Methods: A bibliometric analysis was conducted using the Scopus database to identify the 500 most cited articles published in Interventional Neuroradiology (INR) and the Journal of NeuroInterventional Surgery (JNIS). Each article was categorized by study type, procedure, and pathology. Bibliometric data were analyzed using R and VOSviewer to map influential studies and collaborative networks within the field. Results: A total of 6813 articles were screened. The 500 most cited, comprising 439 from JNIS and 61 from INR, were analyzed. Citation counts averaged 70.71 per article, with the top-cited study reaching 371 citations. A marked increase in high-impact publications occurred from 2020 to 2024, reflecting growing output in the field. The United States led in total publications and citations. Trending topics evolved from early focuses on pediatric cases and aneurysms to current emphases on stroke, thrombectomy, flow diverters, and artificial intelligence. This was confirmed by keyword analysis, demonstrating the dominance of cerebrovascular pathology and minimally invasive techniques in recent neurointerventional research. Conclusion: This analysis highlights the central role of ischemic stroke and aneurysm treatment in neurointervention, with thrombectomy and endovascular therapies driving clinical advances. The field shows increasing global engagement and a shift toward higher-level evidence, reflecting its maturation. While foundational studies remain influential, recent research is poised to define future directions and innovation.